Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo): Side effects or other adverse events
- Population
- People with haemophilia (A or B) undergoing minor oral surgery or dental extractions
- Intervention
- Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid)
- Comparison
- Placebo, no intervention or usual care (with or without placebo)
- Outcome
- Side effects or other adverse events
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) Side effects or other adverse events · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions · Up to 10 days postoperative Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty). Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… (2019) · Cochrane All outcomes | RD 0.034 [-0.32, 0.38] | 2 studies · 59 participants | Low |
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) Side effects or other adverse events · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions · Up to 10 days postoperative Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty). Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… (2015) · Cochrane All outcomesearlier version CD011385.PUB2, superseded | RD 0.034 [-0.32, 0.38] | 2 studies · 59 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery… 2019 · Cochrane All outcomes | 2019-03 | Not listed | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) · People of all ages on VKA or DOAC treatment undergoing oral or dental procedures… · 0 reviews
- Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) · People with hemophilia (A or B) undergoing oral or dental procedures · 0 reviews
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.